Mersana has excellent ADC science. A number of big pharma have bought into the science. However, currently available data leaves a lot to be desired. Their technology platforms are called DolaLock, ...
A few of the key players behind Spirogen have hooked up to create a biotech focused on developing the next generation of antibody-drug conjugates (ADCs). The new company, Femtogenix, is aiming to ...
Compugen Ltd. has announced positive initial experimental results for the first two of five in silico predicted targets for antibody drug conjugate (ADC) cancer therapy disclosed in late 2013. The two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback